Benefits of preoperative MRI in breast cancer surgery studied in a large population-based cancer registry

2015 ◽  
Vol 102 (13) ◽  
pp. 1649-1657 ◽  
Author(s):  
E. L. Vos ◽  
A. C. Voogd ◽  
C. Verhoef ◽  
S. Siesling ◽  
I. M. Obdeijn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Registry ◽  
Large Population ◽  
Population Based ◽  
Cancer Surgery ◽  
Breast Cancer Surgery

scholarly journals The Proportion of Women Who Have a Breast 4 Years after Breast Cancer Surgery: A Population-Based Cohort Study

PLoS ONE ◽  
2016 ◽  
Vol 11 (5) ◽  
pp. e0153704 ◽  
Author(s):  
Joanna C. Mennie ◽  
Pari-Naz Mohanna ◽  
Joseph M O’Donoghue ◽  
Richard Rainsbury ◽  
David A. Cromwell
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Population Based ◽  
Cancer Surgery ◽  
Breast Cancer Surgery

scholarly journals Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
E. C. Inwald ◽  
O. Ortmann ◽  
F. Zeman ◽  
M. Koller ◽  
F. Hofstädter ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Registry ◽  
Large Population ◽  
Population Based ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Even though randomized controlled clinical trials demonstrated improved survival by adjuvant trastuzumab treatment of HER2-positive breast cancer patients, data on its effect in clinical routine are scarce. This study evaluated the use and efficacy of trastuzumab in routine treatment of HER2-positive breast cancer patients. Data from the clinical cancer registry Regensburg (Germany) were analyzed. The present study investigated 6,991 female patients with primary invasive breast cancer. In premenopausal HER2-positive patients a considerable increase of trastuzumab therapy was observed from 58.1% in 2006 to 90.9% in 2011, whereas in postmenopausal patients trastuzumab was rather used on a constant rate of 49.1%. Best overall survival (OS) was found in HER2/steroid hormone receptor-positive patients receiving guideline concordant treatment with trastuzumab plus chemotherapy (CHT) plus antihormone therapy (AHT) with a 7-year OS rate of 96% compared to the non-trastuzumab group with a 7-year OS rate of 92%. In multivariable analysis, HER2-positive patients treated with CHT or AHT who did not get trastuzumab, had a worse 7-year OS (65%,P=0.006versus 79%,P=0.017) than the control groups. This population-based study demonstrated that guideline concordant use of adjuvant trastuzumab improves OS for HER2-positive breast cancer patients treated in routine clinical care.

scholarly journals Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry

2013 ◽  
Vol 139 (2) ◽  
pp. 539-552 ◽  
Author(s):  
E. C. Inwald ◽  
M. Klinkhammer-Schalke ◽  
F. Hofstädter ◽  
F. Zeman ◽  
M. Koller ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Registry ◽  
Large Population ◽  
Population Based ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Prognostic Parameter

scholarly journals Psychological, surgical, and sociodemographic predictors of pain outcomes after breast cancer surgery: A population-based cohort study

Pain ◽  
2014 ◽  
Vol 155 (2) ◽  
pp. 232-243 ◽  
Author(s):  
Julie Bruce ◽  
Alison J. Thornton ◽  
Rachael Powell ◽  
Marie Johnston ◽  
Mary Wells ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Population Based ◽  
Cancer Surgery ◽  
Breast Cancer Surgery ◽  
Sociodemographic Predictors ◽  
Pain Outcomes

scholarly journals Validity of breast cancer surgery treatment information in a state-based cancer registry

2021 ◽  
Author(s):  
Mya L. Roberson ◽  
Hazel B. Nichols ◽  
Stephanie B. Wheeler ◽  
Katherine E. Reeder-Hayes ◽  
Andrew F. Olshan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Registry ◽  
Cancer Surgery ◽  
Breast Cancer Surgery ◽  
Treatment Information
Sign in / Sign up

Export Citation Format

Share Document